Kamada Ltd. announced the appointment of Gwen A. Melincoff to the company’s board of directors. Ms. Melincoff has over 25 years of leadership experience in the biotechnology and pharmaceutical industries. Her experience has spanned venture financing, business development, licensing, mergers and acquisitions, research operations, marketing, product management, project management, and public and private company boards. Ms. Melincoff is currently an advisor to phase 1 Ventures, an accelerator start-up program, and Verge Genomics. From August 2014 to September 2016, she served as Vice President of Business Development at BTG International Inc. From 2004 to 2013, Ms. Melincoff was Senior Vice President of Business Development at Shire Pharmaceuticals.